Notably, two patients with phenotypically heterogeneous tumours harbouring MAP2K1D67N mutations had additional BRAF and NRAS mutations: one with a melanocytoma containing BRAFV600E and NRASQ61R, and another with a melanoma containing BRAFG469R and NRASQ61R mutations. This evidence concerns the gene NRAS and neoplasm.